Ron Bentsur - Chief Executive Officer and Board Member
Ron Bentsur has served as our Chief Executive Officer as of August 2015 and as a director as of October 2015. Ron Bentsur has more than 15 years of experience in the biotech industry. Until 2015 Mr. Bentsur served for more than five years as the Chief Executive Officer Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), culminating in U.S. Food and Drug Administration approval and year-end 2014 launch of Auryxia™ (ferric citrate). Prior to that Mr. Bentsur served as CEO of XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB), a position he held from January 2006 until April 2009. Prior to his tenure at XTL, Mr. Bentsur was with Keryx from 2000-2006, serving as the Keryx’s Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr. Bentsur worked as an investment banker in NYC, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA (Magna Cum Laude), from New York University’s Stern Graduate School of Business.
Gil Hakim - President, IL Operations
Gil Hakim has served us as the President of the Israeli operation since August 2015, and was TheraCoat CEO from August 2010 up to the acquisition of Telormedix in August 2015 and the formation of Urogen Pharma. Mr. Hakim has more than 20 years of experience in the biotech industry. Prior to TheraCoat, Mr. Hakim served in recent years as director of new product development at Medispec Ltd., in-charge of new shockwave based product development in various fields as Cardiology, Vascular, Urology and Dermatology. Prior to Medispec, Mr. Hakim was director of Marketing & Clinical Research at MTRE Advanced Technologies Ltd. (a fully owned subsidiary of Mennen Medical Ltd.) that develops thermoregulation devices. Prior to that, he was Business Development Manager at Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI) (acquired by Johnson & Johnson (NYSE: JNJ) in 2008) which develops biological glue & blood derivative products, and before that he served as European Product Manager at Biosense-Webster (Johnson & Johnson (NYSE: JNJ)) in Belgium, following Johnson & Johnson acquisition of Biosense Israel where he was part of the Research and Development team. Mr. Hakim holds a B.Sc. in Life Sciences from Ben-Gurion University, Israel.
Gary Titus - Chief Financial Officer
Gary S. Titus has served as our Chief Financial Officer since July 2015. Mr. Titus has He has more than 20 years of business experience in the healthcare and biopharmaceutical industries, primarily in senior management roles. Mr. Titus has extensive experience in working with public corporations in a variety of areas, including financial planning and analysis, SEC reporting, investor relations, business development, and corporate strategy. Prior to his appointment as our Chief Financial Officer Mr. Titus has held the position of Chief Financial Officer of BioCardia, Inc. (NASDAQ: BCDA (IPO)). Prior to that Mr. Titus was Senior Vice President and Chief Financial Officer at SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN); as Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences, Inc. (NASDAQ: KOSN) prior to its acquisition by Bristol-Myers Squibb Company (NYSE: BMY), in which transaction he played a significant role; and as Chief Financial Officer and Vice President at Nuvelo, Inc. (later acquired by ARCA Biopharma, Inc. (NASDAQ: ABIO)). Earlier in his career, Mr. Titus held a variety of positions with increasing management responsibilities at other companies, including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc., and Johnson & Johnson’s healthcare division LifeScan, Inc. (NYSE: JNJ). Mr. Titus holds a B.Sc. in Accounting from University of South Florida and a B.Sc. in Finance from University of Florida and is a Certified Public Accountant. Mr. Titus also completed the Global BioExecutive Program at UC Berkeley’s Haas School of Business and is a member of several professional organizations.
Mark P. Schoenberg, MD - Chief Medical Officer
Mark Schoenberg, MD is an internationally recognized expert in the treatment of urothelial cancer. He received his undergraduate degree from Yale University, his MD from The University of Texas (Houston) and served as a resident in surgery and urology at The Hospital of The University of Pennsylvania. Under the auspices of The American Cancer Society, Dr. Schoenberg completed his fellowship in Urologic Oncology in The James Buchanan Brady Urological Institute of The Johns Hopkins University. Dr. Schoenberg is an active investigator and contributor to the peer-reviewed literature on urologic oncology. He has held prominent roles at several major US universities and served as the Bernard Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins University from 2005-2014. Dr. Schoenberg is a founding member of the scientific advisory board of The Bladder Cancer Advocacy Network.
Paul Chu - Vice President of Business Development
Paul Chu has served as our Vice President of Business Development since September 2017. Prior to joining UroGen Pharma, Mr. Chu served as Director, Corporate Business Development for Allergan plc, where he led business development initiatives for Allergan’s Medical Aesthetics and Neurotoxin franchises. In this position, Mr. Chu played a significant role in the successful completion of multiple M&A and licensing transactions, most notably Allergan’s acquisition of Zeltiq Aesthetics, Inc. for $2.5 billion and of privately held LifeCell Corporation, which served as Allergan’s primary entry point into regenerative medicine, for $2.9 billion. Mr. Chu previously held a similar role leading Allergan’s Urology franchise, where he completed the exclusive worldwide license for UroGen’s RTGel™ for use in combination with neurotoxins for the treatment of overactive bladder. Earlier in his career, Mr. Chu held roles of increasing responsibility in finance and commercial operations for Allergan and The Coca-Cola Company. Mr. Chu holds an M.B.A. from the University of Southern California’s Marshall School of Business and a B.A. in Finance and Business Administration from California State University, Fullerton.
Jeffrey Bova - Vice President of Commercial
Jeffrey Bova has served as our Vice President of Commercial since October 2017. Mr. Bova is a pharmaceutical commercial leader with extensive leadership experience across key commercial functional areas, including national sales, marketing and managed care. Mr. Bova joined UroGen Pharma after 20 years at Bayer Healthcare, where he held multiple senior-level sales leadership positions of increasing responsibility. Most recently at Bayer, Mr. Bova served as Vice President of Oncology Sales where he led over 200 field-facing sales representatives marketing well-known brands including Xofigo®, Stivarga® and Nexavar®. Mr. Bova also previously served as Bayer’s Vice President of Marketing for Bayer’s prostate cancer franchise where he designed, developed and led Bayer’s highly successful launch of Xofigo®. Mr. Bova received his M.B.A. from Xavier University and his B.S. in finance and marketing from the University of Cincinnati.
James Ottinger, R.Ph. - Vice President of Regulatory Affairs
James Ottinger has served as our Vice President of Regulatory since October 2017. Mr. Ottinger is a seasoned regulatory executive with over 30 years of strategic regulatory leadership experience and has successfully supported the development, approval, and marketing of multiple new drugs throughout his career. Prior to joining UroGen Pharma, Mr. Ottinger served as Senior Vice President of Global Regulatory Affairs at Teva Pharmaceutical Industries, Inc., where he was responsible for global regulatory oversight of Teva’s portfolio of branded, generic, and over-the-counter products. Previously, Mr. Ottinger was Vice President of Worldwide Regulatory Affairs of Cephalon, Inc. (acquired by Teva). Earlier in his career, Mr. Ottinger held a variety of senior regulatory leadership positions with Premier Research Group Limited, and regulatory positions of increasing responsibility at Wyeth Research (acquired by Pfizer, Inc.). Mr. Ottinger received his B.S. in Pharmacy from the Temple University School of Pharmacy and is a registered pharmacist in the State of Pennsylvania.
Elyse Seltzer, MD - Senior Vice President of Clinical Development
Elyse Seltzer, MD, has served as our Senior Vice President of Clinical Development since December 2017. Prior to joining UroGen, Dr. Seltzer served as Chief Medical Officer of Nabriva Therapeutics, where she was a key member of the management team that took the company public and was responsible for clinical and regulatory strategy and implementation of the Company’s clinical development programs. Dr. Seltzer joined Nabriva from GlaxoSmithKline (GSK), where she was Vice President of Global Clinical Sciences and Operations. Prior to joining GSK, Dr. Seltzer served as Chief Medical Officer at Tengion, a regenerative medicine company, where she established and built the Company’s clinical organization. Dr. Seltzer previously held senior clinical development roles at Centocor and Vicuron, and began her industry career at SmithKline Beecham (now GSK). Before joining the pharmaceutical industry, she was a practicing physician in Infectious Diseases. Dr. Seltzer holds an M.D. from the New York University School of Medicine, completed her Internal Medicine training at the University of Pennsylvania Medical Center and her Infectious Diseases training at Yale New Haven Hospital.